Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,906 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04951635RecruitingPhase 3
Almonertinib after chemoradiation for stage III lung cancer
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Ji'nan, ShandongAges 18 years+ - NCT05351788RecruitingPhase 2
Study drug combo for advanced lung cancer with specific gene results
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Guangzhou, GuangdongAges 18–75 - NCT06247163Recruiting
PET-guided radiation for small cell lung cancer
This trial uses PET scans to guide radiotherapy for people with limited-stage small cell lung cancer, aiming to improve treatment accuracy. It is designed for those whose cancer has not spread extensively.
EssenAges 18 years+ - NCT07363980Enrolling by invitation
Heart CT Study for Rheumatoid Arthritis Patients
This study uses a special heart CT scan to look for early signs of heart disease in people with rheumatoid arthritis. It may help find problems before symptoms start.
AarhusAges 50–75 - NCT06362980RecruitingPhase 1
BPI-1178 plus osimertinib for EGFR-mutated lung cancer
This trial tests a new drug (BPI-1178) combined with osimertinib for advanced lung cancer with EGFR mutations. It’s for people whose cancer has progressed after prior treatment with a third-generation EGFR targeted therapy.
BeijingAges 18 years+ - NCT07028489Recruiting
Studying a standard-care comparison group for advanced EGFR-mutant lung cancer
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
Monterey, CaliforniaAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT07318051Recruiting
Sample collection for cancer research study
This study collects blood and tumor tissue samples from patients with certain untreated cancers to help researchers develop and improve tests. You may be eligible if you have one of the listed cancer types and have not yet started treatment.
Austin, TexasAges 18 years+ - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT06295497Recruiting
Lung cancer screening for non-smokers with a family history
This study tests an artificial intelligence device to screen for lung cancer in people who have never smoked but have a close family member with lung cancer. If you are between 50 and 75 and fit for possible surgery, you may be able to join.
Hong KongAges 50–75 - NCT07066813Recruiting
Lung cancer with air pockets: staging and treatment
This study looks at lung cancers that have air-filled spaces inside them. It explores how the stage of the cancer affects treatment outcomes. If you have this type of lung cancer and have had surgery, this trial may help doctors learn more about your condition.
Changsha, HunanAges Any age - NCT05777603RecruitingPhase 1
Aerosol antibiotics plus pembrolizumab for advanced lung cancer
This trial studies whether inhaled (aerosol) antibiotics combined with pembrolizumab can help people with advanced non-small cell lung cancer that has grown despite standard first treatment. It aims to improve cancer control by testing this new combination in Phase 1 safety and early effectiveness.
Bethesda, MarylandAges 18–120 - NCT07488507Recruiting
Combined biopsy for lung cancer spread in the chest
This trial tests a new way to take tissue samples from suspicious spots in the chest (mediastinum) in people with lung cancer. It aims to see if combining two biopsy methods is safer and more accurate than one alone.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06610734RecruitingPhase 2
Combination treatment for extensive-stage small cell lung cancer
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
SichuanAges 18–75 - NCT07306624RecruitingPhase 2
Nelmastobart plus docetaxel for advanced lung cancer
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Gyeonggi-doAges 19 years+ - NCT04115254Recruiting
MRI-guided focused radiation for certain tumors
This study tests a type of high-precision radiation guided by MRI pictures to treat certain cancers. It may help doctors deliver radiation more accurately while avoiding nearby healthy tissue, but you must be able to safely complete an MRI scan and meet tumor-size and health requirements.
Boston, MassachusettsAges 18 years+ - NCT04170946RecruitingPhase 1
Talazoparib plus chest radiation after extensive small-cell lung cancer
This Phase 1 trial tests whether the medicine talazopib, given along with chest radiation, can better control extensive-stage small-cell lung cancer after initial chemotherapy. It is for people whose cancer has not worsened after finishing standard chemotherapy.
Toronto, OntarioAges 18 years+ - NCT04539977RecruitingPhase 2
PD-L1 antibody plus chemotherapy for limited-stage small-cell lung cancer
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04706754Recruiting
Study of lung cancer information across Canada
This observational study collects information from adults with lung cancer to better understand the disease over time. If you join, it helps researchers learn from real-world experiences rather than testing a new drug.
Brampton, OntarioAges 18 years+ - NCT04777175Recruiting
Looking at immunotherapy for lung cancer with rare gene mutations
This study looks back at patients with advanced non-small cell lung cancer who have specific rare gene changes (mutations). It aims to see how well immunotherapy works for people with these exact mutations.
Changsha, HunanAges 18–75 - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT04951947RecruitingPhase 2
Study drug plus lenvatinib for advanced small-cell lung cancer
This Phase 2 trial tests JS-201 combined with lenvatinib in people with extensive-stage small-cell lung cancer whose first-line treatment didn’t work. It may help by trying a new combination approach after prior therapy failure.
Changsha, HunanAges 18–75 - NCT04966663RecruitingPhase 2
Using blood DNA tests to guide lung cancer treatment
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
Toronto, OntarioAges 18 years+ - NCT05059951Recruiting
Chemotherapy With or Without Immunotherapy for Lung Cancer
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
Changsha, HunanAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,906 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.